QRL Bioscience, a biotechnology company, has raised ₹3 crore in its latest funding round from GVFL.
The fresh funds raised will be used to accelerate the clinical trial phase of its DFU therapy and support the preclinical development of its osteoarthritis treatment.
Founded in 2021 by Senthilkumar Natesan, Kranti Vora and Sanjoy Bhagat, QRL Bioscience is a biotechnology company dedicated to developing personalised, cell-based therapies for chronic degenerative diseases.
QRL previously raised a seed fund from Tie India Angel investors. QRL Bioscience plans to deploy the capital strategically over the next 22 months.
Senthil Natesan, co-founder of QRL Bioscience, said, “We are building an Indian company with a global vision by creating truly novel solutions to improve human health worldwide. Our pioneering personalized medicine using living cell-based therapies will address long-standing health challenges. This funding will bring our DFU product closer to market readiness and advance our osteoarthritis therapy to its next major milestone. We are grateful for the confidence GVFL has placed in us and look forward to welcoming additional strategic partners in this round.”
Mihir Joshi, Managing Director of GVFL, said, “QRL Bioscience is a perfect example of the innovation and scientific rigour that GVFL is committed to supporting. Its living-cell-based therapeutic platform has immense potential to address significant unmet medical needs, both in India and globally. We are excited to partner with QRL as it leads the way in pioneering personalised regenerative medicine.”
